drugset

drugset / Trial / NCT04966143

Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer

NCT04966143 ↗

Phase 0 Unknown 30 enrolled Shanghai Longyao Biotechnology Inc., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

CLDN 18.2 chimeric antigen receptor T cells Clinical research plan for the treatment of recurrent or refractory pancreatic cancer.

Timeline

Start: 2021-08-01
Primary completion: 2023-08-01
Completion: 2024-08-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY011	Cell therapy	—	—

Indications